

Felix C. Tanner
Bernd van der Loo
Sidney Shaw
Helen Greutert
Markus M. Bachschmid
Maria Berrozpe
Izabela Rozenberg
Nenad Blau
Robert Siebenmann
Jürg Schmidli
Peter Meyer
Thomas F. Lüscher

Inactivity of nitric oxide synthase gene in the atherosclerotic human carotid artery

Received: 3 January 2007
Returned for 1. revision: 30 January 2007
1. Revision received: 23 February 2007
Accepted: 26 February 2007
Published online: 15 March 2007

R. Siebenmann, MD
Cardiovascular Surgery
Herzzentrum Hirslanden
Zürich, Switzerland
J. Schmidli, MD
Cardiovascular Surgery, University Hospital
Bern, Switzerland
P. Meyer, MD
Ophthalmology, University Hospital
Basel, Switzerland

F. C. Tanner, MD · B. van der Loo, MD · T. F. Lüscher, MD (✉)
Cardiology, Cardiovascular Center
University Hospital
Rämistrasse 100
8091 Zürich, Switzerland
Tel.: +41-1/255-2121
Fax: +41-1/255-4251
E-Mail cardiotfl@gmx.ch

F. C. Tanner, MD · B. van der Loo, MD ·
H. Greutert · M. Berrozpe, PhD ·
I. Rozenberg · T. F. Lüscher, MD
Cardiovascular Research, Physiology
Institute
University of Zürich
Zürich, Switzerland

F. C. Tanner, MD · I. Rozenberg ·
T. F. Lüscher, MD
Center for Integrative Human Physiology
University of Zürich
Zürich, Switzerland

S. Shaw, PhD
Dept. of Clinical Research, University
Hospital
Bern, Switzerland

M. M. Bachschmid, PhD
Dept. of Biology, University of Konstanz
Konstanz, Germany

N. Blau, PhD
Clinical Chemistry, University Children's
Hospital
Zürich, Switzerland

■ **Abstract** *Objective* Nitric oxide (NO) inhibits thrombus formation, vascular contraction, and smooth muscle cell proliferation. We investigated whether NO release is enhanced after endothelial NO synthase (eNOS) gene transfer in atherosclerotic human carotid artery ex vivo. *Methods and Results* Western blotting and immunohistochemistry revealed that transduction enhanced eNOS expression; however, neither nitrite production nor NO release measured by porphyrinic microsensor was altered. In contrast, transduction enhanced NO production in non-atherosclerotic rat aorta and human internal mammary artery. In transduced carotid artery, calcium-dependent eNOS activity was minimal and did not differ from control conditions. Vascular tetrahydrobiopterin concentrations did not differ between the experimental groups. Treatment of transduced carotid artery with FAD, FMN, NADPH, L-arginine, and either sepiapterin or tetrahydrobiopterin did not alter NO release. Superoxide formation was similar in transduced carotid artery and control. Treatment of transduced carotid artery with superoxide dismutase (SOD), PEG-SOD, PEG-catalase did not affect NO release. *Conclusions* eNOS transduction in atherosclerotic human carotid artery results in high expression without any measurable activity of the recombinant protein. The defect in the atherosclerotic vessels is neither caused by cofactor deficiency nor enhanced NO breakdown. Since angioplasty is performed in atherosclerotic arteries, eNOS gene therapy is unlikely to provide clinical benefit.

■ **Key words** Nitric oxide synthase – gene therapy – adenoviral vector – atherosclerosis – endothelium

List of abbreviations

| | |
|------------------------------|--|
| AdeNOS | adenoviral vector for expression of human eNOS |
| AdhPAP | adenoviral vector for expression of human placental alkaline phosphatase |
| ADMA | asymmetric dimethylarginine |
| BH ₄ | tetrahydrobiopterin |
| CA | carotid arteries |
| DMEM | dulbecco's modified eagle medium |
| DTT | dithiothreitol |
| EDTA | ethylenediaminetetraacetic acid |
| EDRF | endothelium-derived relaxing factor |
| EGTA | ethylene glycol tetraacetic acid |
| eNOS | endothelial NO synthase |
| FAD | flavin adenine dinucleotide |
| FCS | fetal calf serum |
| FITC | fluorescein isothiocyanate |
| FMN | flavin mononucleotide |
| hPAP | human placental alkaline phosphatase |
| iNOS | inducible nitric oxide synthase |
| L-NAME | N(G)-nitro-L-arginine methyl ester |
| MA | internal mammary artery |
| NADPH | nicotine adenine dinucleotide phosphate |
| NMA | N-monomethylarginine |
| nNOS | neuronal nitric oxide synthase |
| NO | Nitric oxide |
| NO ₂ ⁻ | nitrite |
| O ₂ ⁻ | superoxide |
| oxLDL | oxidized low density lipoprotein |
| PEG-catalase | polyethylene glycol catalase |
| PEG-SOD | polyethylene glycol superoxide dismutase |
| PVDF | polyvinylidene fluoride |
| SDS-PAGE | SDS-polyacrylamide gel electrophoresis |
| SOD | superoxide dismutase |
| VSMC | vascular smooth muscle cell |

Introduction

Gene therapy is a promising therapeutic approach for restenotic lesions, and for in-stent-restenosis in particular [21, 32]. Nitric oxide (NO) inhibits platelet aggregation, induces vascular relaxation, and impairs vascular smooth muscle cell (VSMC) proliferation by specific actions on cell cycle progression [11, 12, 25]. Moreover, NO counterregulates the induction of adhesion molecule expression and leucocyte accumulation as well as other inflammatory alterations occurring in atherosclerotic arteries [3]. Therefore, overexpression of endothelial NO synthase (eNOS) seems a reasonable concept for the local treatment of restenotic lesions. This is particularly plausible as balloon dilatation is performed in athero-

sclerotic vessels which exhibit reduced eNOS expression [17].

NO formation is catalyzed by at least 3 different isoforms of NOS. Neuronal NOS is constitutively expressed in neurons and some other cell types; it generates low levels of NO. Expression of inducible NOS (iNOS) can be induced by cytokines in many different cell types; this isoform generates high levels of NO. Endothelial NOS is constitutively expressed in endothelial cells and some other cell types, and similar to nNOS, it releases low levels of NO. The major reason responsible for the different enzyme kinetics is the calcium-dependency of nNOS and eNOS [9].

Normal function of eNOS is critically dependent on the availability of the substrate L-arginine and several cofactors as well. Indeed, L-arginine administration increases endothelial NO synthesis in hypercholesterolemia [7], and tetrahydrobiopterin (BH₄) infusion restores endothelium-dependent relaxation in hypercholesterolemic humans [22]. In addition, reduced NO activity may not only be caused by diminished synthesis, but also by enhanced catabolism of the radical, as the half-life of NO is determined by its reaction with oxyhemoglobin and superoxide (O₂⁻) [31]. Thus, atherosclerotic arteries may have a diminished NO production because of both reduced cofactor concentration and enhanced O₂⁻ production [18]. As treatment of restenosis by gene delivery would have to be performed in such diseased vessels, we examined whether eNOS transduction into atherosclerotic human carotid arteries (CA) *ex vivo* is indeed followed by an enhanced NO production.

Methods

Recombinant adenovirus

An adenoviral vector for expression of human placental alkaline phosphatase (AdhPAP) was prepared as described [19]. The vector for expression of eNOS (AdeNOS) was provided by Dr Stefan Janssens, Leuven, Belgium [1]. The titer of purified viruses was determined by plaque assay on 293 cells as described [14]. Viral titers ranged from 2×10^{10} to 2×10^{11} pfu/ml for all preparations. The titer of wild type virus was determined by plaque assay on A549 cells using the same conditions and was below 1×10^9 pfu/ml.

Cell culture, tissue culture, transduction

293 cells and A549 cells were obtained from ATCC and cultured as recommended. CA tissue specimens were obtained from 50 human donors undergoing endarterectomy. The study was reviewed by the ethics committee of the University Hospital, and the patients

gave their informed consent prior to inclusion in the study. Mean age was 71 ± 8 ; males: 72%; smokers: 52%; hypercholesterolemia; 56%; hypertension: 70%; diabetes: 34%. 86% of patients were treated with aspirin, 64% with a statin. No difference between eNOS expression, risk factors, and specific medication was observed in the CA specimens. All specimens exhibited macroscopic evidence of atherosclerotic changes (fatty streaks, advanced lesions, atheromas). The time window between excision of CA and beginning of gene transfer was between 3 and 6 hours for all the experiments. Specimens were cut into small pieces (5×5 mm) under sterile conditions, while tissue pieces with large necrotic areas were avoided as the material was too friable. Internal mammary artery tissue segments were obtained from patients undergoing coronary artery bypass grafting. Atherosclerotic changes were excluded by a stereo microscope (Leitz, Heerbrugg, Switzerland) at $30\times$ magnification. Rat aorta served as additional control for some experiments. Tissue pieces were incubated with a viral titer of 1×10^9 pfu/ml for 2 hours at 37° and then kept in DMEM with 10% FCS for an additional 48 hours [20]. Tissue from CA, internal mammary artery and rat aorta was treated in an identical manner. Transduction was confirmed by staining of AdhPAP transfected specimens with NBT/BCIP (GIBCO) as described [23], and tissue specimens were analyzed by a stereo microscope (Leitz, Heerbrugg, Switzerland) at $30\times$ magnification.

■ Western blot analysis

Western blot analysis was performed on tissue specimens as described [24]. 60 μ g protein were loaded per lane, resolved by SDS-PAGE under reducing conditions, blotted onto PVDF membranes and analyzed by chemiluminescence (Amersham). Equal loading of proteins was controlled for by staining with Ponceau S as well as by blotting for α -tubulin.

■ Immunohistochemistry

Tissue specimens were prepared as described [13]. Specimens were incubated with anti-eNOS monoclonal antibody (N30020; Transduction Laboratories, Lexington, USA) at 4° overnight. Immunostaining was performed with an FITC-conjugated goat anti-mouse antibody (F479; Dako, Glostrup, Denmark) at 1:10 dilution followed by counterstaining with Evans blue 0.1% (Merck, Darmstadt, Germany) and mounting in glycerol medium (Dako) [13]. Negative controls were obtained by replacing the primary antibody with an irrelevant anti CD18 antibody (1110; Monosan, Uden, Netherlands) as well as with antibodies for iNOS and nNOS (N32020 and N31020, respectively; Transduction Labo-

ratories); positive controls were generated on human tonsil for eNOS, porcine pituitary gland for nNOS, and human macrophage cultures for iNOS [13].

■ Nitrite release

After transduction, tissue pieces were kept in DMEM with 20% FCS at 37° for 48 hours. This procedure has been shown to activate eNOS both in VSMC [25] and in vascular tissue [26]. Tissue pieces were homogenized and subsequently diluted in water. Quantitation of nitrite was performed as described [2].

■ NO release

After transduction, tissue pieces were treated as described for nitrite measurement. NO release was stimulated by 10^{-5} M calcium ionophore A23187, and NO was measured by a porphyrinic microsensor as described [28].

■ eNOS activity

Vessels were homogenized in 600 μ l of a solution containing 50 mM Tris pH 7.4, 250 mM sucrose, and 2 mM EDTA. 50 μ l of homogenate was incubated at room temperature in 200 μ l incubation medium with or without 2 mM L-NAME, containing 1 mM nicotine adenine dinucleotide phosphate (NADPH), 4 mM CaCl_2 , 1 mM DTT, 15 μ M tetrahydrobiopterin, 10 μ M flavin adenine dinucleotide (FAD), 10 μ M flavin mononucleotide (FMN), 10 μ g/ml calmodulin, 0.2 μ Ci 3H-arginine, and 50 μ M unlabeled L-arginine. The reaction was stopped after 1 h by addition of HEPES (100 mM), EDTA (4 mM), EGTA (2 mM) pH 5.5 containing unlabeled amino acid markers. For some experiments, calcium was omitted in the buffer. Radiolabeled arginine was separated from citrulline on silica gel thin-layer chromatography plates using chloroform:methanol: NH_4OH :water 1:4:2:1 vol/vol as solvent and developed with fluoroldehyde-o-phthalaldehyde reagent. The relevant bands were scraped from the plate and counted in a scintillation counter. Citrulline production was expressed as dpm citrulline/h/g wet weight.

■ Superoxide release

After transduction, tissue pieces were kept in DMEM with 20% FCS at 37° for 48 hours. O_2^- production was measured by coelenterazine chemoluminescence as described using a Turner Design Model TD-20/20 luminometer (Turner Designs, Sunnyvale, CA) [27]. O_2^- re-

lease rate was expressed as relative light units/minute/mg dry weight. Absolute values of O_2^- release were determined with known quantities of xanthine and xanthine oxidase by the SOD inhibitable cytochrome c reduction using the molar extinction coefficient for cytochrome c ($21 \text{ mmol/l} \cdot \text{cm}^{-1}$) and expressed as nmol/minute/mg dry weight [18].

BH₄ concentrations

BH₄ was measured in non-transduced, control vector treated, and eNOS vector treated carotid artery as described [10].

Statistics

Results represent the mean value of 5 to 8 experiments as indicated in the text. Data are expressed as mean \pm standard error of the mean (S.E.M.) and statistical com-


parisons were performed using analysis of variance (ANOVA). A two-tailed p value of less than 0.05 was considered to indicate a significant difference.

Results

Expression of eNOS

Adenoviral transduction of human CA was assessed by human placental alkaline phosphatase (hPAP). NBT/BCIP staining revealed the presence of functional hPAP in CA transduced with hPAP adenovirus (hPAP), but not with control adenovirus ($\Delta E1$) nor under non-transduced conditions indicating good transduction using this vector (Fig. 1A). eNOS expression in human CA after adenoviral transduction was first examined by Western blot analysis, which demonstrated a high expression after transduction with the eNOS adenovirus (eNOS), while the protein was barely detectable in the control adenovirus group ($\Delta E1$) nor under non-trans-

Fig. 1 **A.** Placental alkaline phosphatase (hPAP) expression in transduced atherosclerotic human carotid artery (CA). Intimal side observed by stereomicroscope at 30x magnification. NBT/BCIP staining demonstrates hPAP in CA transduced with hPAP adenovirus (hPAP), but not control adenovirus ($\Delta E1$) nor under non-transduced conditions. **B.** Endothelial nitric oxide synthase (eNOS) expression in CA. Western blot analysis demonstrates eNOS in CA transduced with eNOS adenovirus (eNOS), but not control adenovirus ($\Delta E1$) nor under non-transduced conditions. **C.** eNOS expression in CA. Immunohistochemical analysis demonstrates eNOS protein in CA transduced with eNOS adenovirus (eNOS), while there is only very faint staining with control adenovirus ($\Delta E1$) and no staining under non-transduced conditions (lower row). The presence of an intact endothelium is demonstrated by staining for von Willebrand Factor (middle row). An H&E staining is presented as well (upper row). Magnification 400x



duced conditions (Fig. 1B). Immunohistochemical analysis of eNOS expression revealed a strong signal in endothelial and to a lesser degree in subendothelial cells of transduced specimens. Consistent with the Western blots, no significant staining was detected in control adenovirus transduced tissues or in non-transduced samples (Fig. 1C). This pattern of eNOS expression in atherosclerotic carotid artery was observed in most transduced specimens; however, in 2 out of 10 samples, eNOS expression was not clearly increased as compared to control specimens, which is consistent with the heterogeneous morphology of the atherosclerotic tissue. Expression of iNOS and nNOS was examined in serial sections; no staining was observed in non-transduced and transduced specimens (data not shown).

Western blotting revealed that eNOS expression was 8.75-fold higher in non-atherosclerotic human internal mammary artery (MA) as compared side by side to atherosclerotic carotid artery (p < 0.05; n = 4–5; Fig. 2, left panel). Indeed, only prolonged exposure times permitted to detect a signal for eNOS in the carotid artery samples. After adenoviral transduction, eNOS expression increased by 10.7-fold in MA (p < 0.01 for control vs. eNOS

and for $\Delta E1$ vs. eNOS; n = 5; Fig. 3, left panel) and by 9.9-fold in CA (p < 0.05 for control vs. eNOS and for $\Delta E1$ vs. eNOS; n = 5; Fig. 3, right panel). Moreover, eNOS expression was similar in MA and CA transduced with eNOS (p = 0.55; n = 5).

■ Release of NO

NO release from CA after eNOS gene transfer was first assessed by measuring nitrite (NO_2^-) tissue levels. 48 hours after transduction, the cumulative nitrite level was $0.378 \pm 0.249 \mu\text{mol/g}$ for non-transduced conditions, $0.854 \pm 0.495 \mu\text{mol/g}$ for control adenovirus ($\Delta E1$), and $1.110 \pm 0.696 \mu\text{mol/g}$ for eNOS adenovirus (eNOS) (p = 0.76 for control vs. eNOS; p = 0.46 for control vs. $\Delta E1$; p = 0.70 for Ad $\Delta E1$ vs. AdeNOS; n = 8; Fig. 4, right panel). To compare NO release from CA with that from an arterial tissue without atherosclerotic changes, a parallel set of experiments was performed in rat aorta. In contrast to CA, eNOS gene transfer enhanced NO release from this tissue. Indeed, 48 hours after transduction, the nitrite tissue level was $0.914 \pm 0.562 \mu\text{mol/g}$ for non-trans-

Fig. 2 Endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) release in human arteries. eNOS expression (left panel) is determined by Western blots and indicated in arbitrary densitometric units; expression is higher in internal mammary artery (MA) as compared to atherosclerotic carotid artery (CA). NO release (right panel) is measured by a porphyrinic microsensor and it is higher in MA than CA





Fig. 3 Endothelial nitric oxide synthase (eNOS) expression in transduced human arteries. Expression is determined by Western blots and indicated in arbitrary densitometric units. The eNOS signal is related to that of α -tubulin (αT) as loading control. eNOS expression is high in internal mammary artery (MA) and atherosclerotic carotid artery (CA) transduced with eNOS adenovirus (eNOS), while a weak signal is detected in both vessels with control adenovirus ($\Delta E1$) or under non-transduced conditions



duced conditions, 6.590 ± 1.362 $\mu\text{mol/g}$ for control adenovirus (ΔE1), and 11.112 ± 1.493 $\mu\text{mol/g}$ for eNOS adenovirus (eNOS) ($p=0.0001$ for control vs. eNOS; $p<0.01$ for control vs. ΔE1 ; $p<0.05$ for ΔE1 vs. eNOS; $n=5$; Fig. 4, left panel). An effect of control adenovirus on NO release after eNOS transduction has been observed in non-atherosclerotic tissue in previous studies as well [25, 26]. To confirm that eNOS gene transfer did not affect NO production in CA, the release of NO was also measured by a porphyrinic microsensor upon stimulation with 10^{-5} M calcium ionophore A23187. All the measurements were performed within 10 seconds. NO release was similar under non-transduced conditions and in tissue treated with control adenovirus (ΔE1) or with eNOS adenovirus (eNOS) ($p=0.82$ for control vs. ΔE1 ; $p=0.45$ for control vs. eNOS; $p=0.92$ for ΔE1 vs. eNOS; $n=8$; Fig. 4, upper insert).

To study NO production in a non-atherosclerotic human tissue as well, NO release from transduced MA was examined. As compared to control conditions (100%; 85 ± 27 nM), NO production of this tissue was 89 ± 22 % (80 ± 40 nM) for control adenovirus (ΔE1) and 254 ± 40 % (228 ± 106 nM) for eNOS adenovirus (eNOS) ($p<0.005$ for control vs. eNOS; $p<0.005$ for ΔE1 vs. eNOS; $p=0.95$ for control vs. ΔE1 ; $n=4$; Fig. 5A). MA NO production under non-transduced conditions was 85 ± 27 nM and hence much higher as compared to CA (5 ± 3 nM; $n=9$; $p=0.001$; Fig. 2, right panel). Again, NO production in CA was not affected by transduction of eNOS, while that in MA increased (Fig. 5B).

To assess whether the atherosclerotic tissue deteriorated during the 48 h incubation period, NO release was compared in freshly isolated versus incubated CA and found to be identical (fresh: 8.0 ± 4.6 nM; incubated: 7.5 ± 2.6 nM; $n=4$; $p=0.93$). Consistent with a minimal NO production, eNOS activity was barely detectable in CA; indeed, the values were several thousand fold lower as compared to non atherosclerotic arterial tissue from

various species including humans [8, 10]. In the absence of calcium, no enzyme activity was detected, indicating that iNOS does not contribute to this activity. Enzyme activity was not affected by transduction ($p=\text{n.s.}$ for non-transduced vs. eNOS; $p=\text{n.s.}$ for non-transduced vs. ΔE1 ; $p=\text{n.s.}$ for ΔE1 vs. eNOS; $n=5$; Table). To address whether cofactor deficiency in the atherosclerotic tissue was responsible for the lack of enhanced NO production after transduction, tissue concentrations of BH_4 were determined. BH_4 concentrations were similar for non-transduced (3.17 ± 1.18 pmol/mg), ΔE1 -transduced (6.20 ± 2.27 pmol/mg), and eNOS-transduced tissue (7.63 ± 4.72 pmol/mg; $n=3$; $p=\text{n.s.}$). Moreover, tissue specimens were incubated with BH_4 (10^{-4} M), FAD (5×10^{-6} M), FMN (5×10^{-6} M), NADPH (5×10^{-4} M), and L-arginine (10^{-4} M) for 3 hours before NO was measured. NO release was not altered in all three experimental groups (non-transduced, ΔE1 , eNOS) as compared to conditions without cofactor addition ($n=4$; p values ranging from 0.59 to 0.99; Table). Similar results were obtained when these cofactors were present during the 48 h period between transfection and measurement of NO release (all values <15 nM NO; $n=4$; p values ranging from 0.67 to 0.93; data not shown). Further, no change in NO release was observed when sepiapterin instead of BH_4 was used (all values <15 nM NO; $n=2$; data not shown).

■ Release of O_2^-

To analyze whether increased O_2^- generation in transduced CA could lead to enhanced catabolism of NO, the release of O_2^- was measured by coelenterazine chemoluminescence. O_2^- production was 0.245 nmol/min/mg dry weight for non-transduced conditions, 0.335 nmol/min/mg dry weight for control adenovirus (ΔE1), and 0.254 nmol/min/mg dry weight for eNOS aden-

Fig. 4 Nitric oxide (NO) and superoxide (O_2^-) production in transduced atherosclerotic human carotid artery (CA). Nitrite production is similar in CA transduced with eNOS adenovirus (eNOS) as compared to control adenovirus (ΔE1) and non-transduced conditions. In contrast, nitrite production is significantly higher in rat aorta transduced with eNOS as compared to ΔE1 and non-transduced conditions. Nitric oxide (NO) production is shown in the upper insert and is similar in CA transduced with eNOS as compared to ΔE1 and non-transduced conditions. Superoxide (O_2^-) production is shown in the lower insert and is also similar in CA transduced with eNOS as compared to ΔE1 and non-transduced conditions





Fig. 5 Release of nitric oxide (NO) in transduced human arteries measured by porphyrinic microsensor. **A.** NO release is higher in internal mammary artery (MA) transduced with endothelial nitric oxide synthase (eNOS) adenovirus as compared to control adenovirus ($\Delta E1$) or to control conditions. Left panel: original recording; right panel: average values of 4 independent experiments. **B.** NO release is higher in MA as compared to atherosclerotic carotid artery under nontransduced conditions (left panel), after treatment with $\Delta E1$ (middle panel), and after transduction with eNOS (right panel)



ovirus (eNOS) ($p=0.97$ for non-transduced vs. eNOS; $p=0.59$ for non-transduced vs. $\Delta E1$; $p=0.71$ for $\Delta E1$ vs. eNOS; $n=5$; Fig. 4 lower insert). To address whether superoxide generated in the atherosclerotic tissue reacted with NO, the porphyrinic microsensor measurement was repeated in the presence of superoxide dismutase (SOD; 25 U/ml) or polyethylene glycol superoxide dismutase (PEG-SOD; 300 U/ml). NO release was not altered in all three experimental groups (non-transduced, $\Delta E1$, eNOS) as compared to conditions without addition of SOD or PEG-SOD (p values ranging from 0.45 to 0.99; $n=5$; Table). To assess whether H_2O_2 was involved in NO breakdown, the microsensor measurement was repeated in the presence of PEG-catalase (1000 U/ml). NO release was not altered in all three experimental groups (non-transduced, $\Delta E1$, eNOS) as compared to conditions without addition of PEG-catalase (p values ranging from

0.43 to 0.95; $n=4$; Table). As a positive control for the action of PEG-SOD and PEG-catalase preparations, the effect of 300 U/ml of PEG-SOD and 1000 U/ml of PEG-catalase on conversion of dichlorodihydrofluorescein diacetate to dichlorodihydrofluorescein was determined. PEG-SOD reduced the conversion induced by 1 mM SIN-1 to $26 \pm 0.5\%$ of control ($p < 0.001$; $n=6$). PEG-catalase also inhibited conversion induced by 1 mM H_2O_2 ($54 \pm 0.6\%$ of control; $p < 0.0001$; $n=6$).

Discussion

This study demonstrates that adenoviral transduction of atherosclerotic human CA results in marked eNOS expression without enhancing NO release, indicating that the recombinant enzyme is dysfunctional in ather-

Table Activity of endothelial nitric oxide synthase (NOS) and release of nitric oxide (NO) in the presence of cofactors, superoxide dismutase (SOD; 25 U/ml), PEG-SOD (300 U/ml), PEG-catalase (1000 U/ml) in transduced atherosclerotic human carotid artery (CA). NOS activity was determined by citrulline assay, NO production by porphyrinic microsensor. The cofactors L-arginine (10^{-4} M), BH_4 (10^{-4} M), FAD (5×10^{-6} M), FMN (5×10^{-6} M), NADPH (5×10^{-4} M) were added for 30 minutes prior to measurement. All the treatments did not significantly improve NOS activity or NO release ($p=n.s.$)

| Parameter | Control | $\Delta\Delta E1$ | eNOS |
|--------------------------------------|----------------|-------------------|-----------------|
| NOS activity (pmol NO/h/g protein) | 4.6 \pm 4.6 | 27.1 \pm 10.3 | 24.3 \pm 14.1 |
| NO release without cofactors (nM) | 5.0 \pm 5.0 | 5.8 \pm 3.9 | 10.8 \pm 4.0 |
| NO release with cofactors (nM) | 13.0 \pm 6.0 | 8.3 \pm 5.0 | 5.0 \pm 5.0 |
| NO release without SOD (nM) | 5.2 \pm 5.2 | 2.0 \pm 2.0 | 7.8 \pm 5.2 |
| NO release with SOD (nM) | 5.2 \pm 5.2 | 9.8 \pm 6.0 | 5.2 \pm 5.2 |
| NO release without PEG-SOD (nM) | 4.0 \pm 2.3 | 6.6 \pm 4.2 | 8.5 \pm 3.1 |
| NO release with PEG-SOD (nM) | 6.6 \pm 3.8 | 4.0 \pm 2.3 | 10.1 \pm 3.5 |
| NO release without PEG-catalase (nM) | 5.3 \pm 1.8 | 1.8 \pm 1.8 | 2.8 \pm 2.8 |
| NO release with PEG-catalase (nM) | 5.0 \pm 5.0 | 8.3 \pm 3.1 | 3.5 \pm 3.5 |

osclerotic human vessels. Expression of the transduced genes in CA was observed in both endothelium and subendothelial cells. After eNOS transduction, VSMC and adventitial fibrocytes can release NO [8, 25]; thus, medial and adventitial cells may contribute to NO release in transduced vessels. Therefore, endothelial damage or even denudation during PTCA is not a reason to refrain from eNOS gene transfer. However, the lack of NO release indicates that eNOS gene transfer is not a reasonable gene therapy strategy for restenosis or atherosclerotic vascular disease.

A higher eNOS expression in transduced atherosclerotic CA as compared to control tissue was observed in 8 out of 10 samples. In the other two samples, no clear increase in eNOS expression was present as compared to control. Hence, transfection of atherosclerotic CA is somewhat variable, presumably due to its morphological heterogeneity. Nevertheless, most of the samples exhibited a higher eNOS expression as compared to control. Therefore, the missing increase in NO release in all the transduced samples can not be explained by variability of transfection. NO production after eNOS transduction was determined by both nitrite formation and NO release. Neither method detected an enhanced NO production in transduced CA as compared to control tissue. Rat aorta and human internal mammary artery served as non-atherosclerotic controls for NO formation after eNOS transduction. These controls were chosen because of the obvious difficulties to obtain non-atherosclerotic human CA. Experiments were performed in parallel with those in CA and revealed both an enhanced eNOS expression and NO production after eNOS transduction, demonstrating that overexpression of eNOS enhances NO release only in non-atherosclerotic tissue; therefore, similar to endogenous eNOS, the transduced

enzyme seems to be dysfunctional in atherosclerotic tissue. The lack of NO release is not only consistent with dysfunction of eNOS, but also with absence of iNOS expression in the CA tissue; as the specimens originated from long-standing lesions with presumably stable plaques, inflammation probably does not play a major role in these lesions any longer.

In the rat aorta, the control adenovirus had some effect on nitrite formation, suggesting that the vector induces the endogenous enzyme. Consistent with this interpretation, there was a very faint staining for eNOS in the $\Delta E1$ transduced CA. As nitrite formation in the latter was neither altered by $\Delta E1$ nor eNOS adenovirus, atherosclerosis may induce a similar functional defect of both the endogenous and the recombinant enzyme. However, the control vector did not have any effect on NO formation as determined by the porphyrinic microsensor in the human internal mammary artery. This observation offers the alternative explanation that the effect of $\Delta E1$ on nitrite formation does not depend on NO or, with lower probability, that it is influenced by the type of species or vessel involved.

Activity of eNOS in CA was determined by a highly sensitive modification of the citrulline assay and was almost undetectable both under control conditions and after eNOS transduction. Indeed, the values were several thousand fold lower as compared to non-atherosclerotic arterial tissue from various species including humans [5, 16]. This observation demonstrates that eNOS activity is not enhanced after transduction and is consistent with the minimal NO release from the atherosclerotic tissue. For catalysis of NO formation from L-arginine, eNOS requires several cofactors. Indeed, FAD and FMN are necessary for electron transport from NADPH to oxygen, while BH_4 is required for efficient generation of NO from reduced oxygen and L-arginine. Deficiency of these cofactors may hamper the function of the endogenous as well as the recombinant enzyme. In fact, atherosclerotic vessels contain lower cofactor concentrations and release less NO as compared to normal vessels, and cofactor infusion can improve NO formation [7, 22, 31]. Hence, BH_4 concentrations in CA after eNOS transduction were determined. Concentrations of the cofactor did not differ in transduced as compared to control tissue. Further, NO release from CA after eNOS transduction was examined in the presence of cofactor supplementation. Under these conditions, however, NO release did not differ in transduced as compared to control tissue. Although some degradation of cofactors in culture can not be excluded, these data suggest that cofactor deficiency alone can not account for the dysfunction of the recombinant enzyme. Hence, the lack of eNOS activity in transduced atherosclerotic tissue must be related to other mechanisms as well. Indeed, it is conceivable that the presence of oxidized LDL in the atherosclerotic tissue may impair signal transduction activation of eNOS;

furthermore, competitive inhibitors of eNOS such as ADMA may be synthesized in the endothelium causing decreased eNOS activity [4].

In case of suboptimal BH₄ concentrations, uncoupling of eNOS occurs, and the enzyme itself becomes a source of O₂⁻. Hence, the lack of an increase in NO production after eNOS transduction may be related to increased O₂⁻ formation resulting in NO catabolism. Therefore, O₂⁻ generation in CA was determined. O₂⁻ release did not differ in eNOS transduced tissue as compared to control conditions, indicating that enhanced NO catabolism is not a probable reason for the unaltered NO release after transduction, and supporting the interpretation that cofactor deficiency can not be the sole reason for the dysfunction of recombinant eNOS. Consistent with these observations, NO production remained identical in the presence of SOD and PEG-SOD. Similarly, PEG-catalase did not affect the formation of NO, indicating that NO catabolism by H₂O₂ can be excluded as a reason for the unaltered NO release after transduction as well.

In theory, eNOS gene transfer is a very reasonable therapeutic strategy for vascular disease, as NO does not only inhibit VSMC proliferation, but also impairs thrombus formation eliminating a major source of mitogens for VSMC, and interferes with adhesion molecule expression as well as leucocyte invasion [3, 12]. In addition, expression of eNOS is reduced in atherosclerotic tissue, demanding substitution by a recombinant enzyme [17]. For the treatment of restenosis, however, eNOS gene transfer is unlikely to provide clinical bene-

fit; such vessels are severely atherosclerotic, and, according to our data, transduction would result in expression of an inactive enzyme. Since eNOS gene transfer has been described to reduce vascular smooth muscle cell proliferation [6] and restenosis in a pig and a mouse model [15, 29, 30], the inactivity of recombinant eNOS in the human CA is surprising; however, differences in gender, in the degree of atherosclerosis, and/or in the pathogenesis of atherosclerosis may well account for the different activity of recombinant eNOS in these models and the human tissue. Thus, transduction of a gene can result in unexpected features in the respective human tissue, indicating that ex vivo studies with the relevant tissue should be performed before starting clinical trials. In contrast to restenosis, coronary artery bypass graft disease still represents a promising target for eNOS gene transfer. Indeed, the saphenous vein is not atherosclerotic when implanted as bypass graft. Moreover, eNOS transduction inhibits biological features of bypass graft disease in the human saphenous vein ex vivo [26]. Therefore, in its current state, successful application of gene transfer technology for treating vascular diseases requires a specifically tailored strategy, which does not only take into account efficiency of transduction and duration of expression, but also the biological characteristics of the respective human tissue.

■ **Acknowledgements** This study was supported by the Swiss National Science Foundation (Grant Nr. 31-47119.96 and 32-51069.97), Swiss Heart Foundation, Hartmann Müller Foundation.

References

1. Alcorn JL, Gao E, Chen Q, Smith ME, Gerard RD, Mendelson CR (1993) Genomic elements involved in transcriptional regulation of the rabbit surfactant protein-A gene. *Mol Endocrinol* 7: 1072–1085
2. Barton M, Vos I, Shaw S, Boer P, d'Uscio LV, Gröne HJ, Rabelink TJ, Lattmann T, Moreau P, Luscher TF (2000) Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. *J Am Soc Nephrol* 11:835–846
3. Berendji-Grun D, Kolb-Bachofen V, Kroncke KD (2001) Nitric oxide inhibits endothelial IL-1(β)-induced ICAM-1 gene expression at the transcriptional level decreasing Sp1 and AP-1 activity. *Mol Med* 7:748–754
4. Cannon RO (1998) Role of nitric oxide in cardiovascular disease: focus on the endothelium. *Clinical Chemistry* 44: 1809–1819
5. Chen AF, Jiang SW, Crotty TB, Tsutsui M, Smith LA, O'Brien T, Katusic ZS (1997) Effects of in vivo adventitial expression of recombinant endothelial nitric oxide synthase gene in cerebral arteries. *Proc Natl Acad Sci USA* 94: 12568–12573
6. Cooney R, Hynes SO, Duffy AM, Sharif F, O'Brien T (2006) Adenoviral-mediated gene transfer of nitric oxide synthase isoforms and vascular cell proliferation. *J Vasc Res* 43:462–472
7. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP (1992) L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. *J Clin Invest* 90: 1248–1253
8. d'Uscio LV, Baker TA, Mantilla CB, Smith L, Weiler D, Sieck GC, Katusic ZS (2001) Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. *Arterioscler Thromb Vasc Biol* 21: 1017–1022
9. Förstermann U (2006) Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. *Biol Chem* 387: 1521–1533
10. Fukushima T, Nixon JC (1980) Analysis of reduced forms of biopterin in biological tissues and fluids. *Anal Biochem* 102:176–188
11. Lauer T, Kleinbongard P, Preik M, Rauch BH, Deussen A, Feelisch M, Strauer B, Kelm M (2003) Direct biochemical evidence for eNOS stimulation by bradykinin in the human forearm vasculature. *Basic Res Cardiol* 98: 84–89
12. Lüscher TF, Vanhoutte PM (1990) The Endothelium: Modulator of Cardiovascular Function. CRC Press, Boca Raton
13. Meyer P, Champion C, Schlötzer-Schrehardt U, Flammer J, Haefliger IO (1999) Localisation of nitric oxide isoforms in porcine ocular tissues. *Current Eye Research* 18:375–380

14. Mittereder N, March KL, Trapnell BC (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. *J Virology* 70: 7498–7509
15. Mujynya-Ludunge K, Viswambharan H, Driscoll R, Ming X-F, von Segesser LK, Kappenberger L, Yang Z, Vassalli G (2005) Endothelial nitric oxide synthase gene transfer restores endothelium-dependent relaxations and attenuates lesion formation in carotid arteries in apolipoprotein E-deficient mice. *Basic Res Cardiol* 100:102–111
16. Nelson SH, Steinsland OS, Wang Y, Yallampalli C, Dong YL, Sanchez JM (2000) Increased nitric oxide synthase activity and expression in the human uterine artery during pregnancy. *Circ Res* 87: 406–411
17. Oemar BS, Tschudi MR, Godoy N, Brovkovith V, Malinski T, Luscher TF (1998) Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. *Circulation* 97: 2494–2498
18. Ohara Y, Peterson TE, Harrison DG (1993) Hypercholesterolemia increases endothelial superoxide anion production. *J Clin Invest* 91:2546–2551
19. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG (1994) Gene therapy for vascular smooth muscle cell proliferation after arterial injury. *Science* 265:781–784
20. Reikhter MD, Simari RD, Work CW, Nabel GJ, Nabel EG, Gordon D (1998) Gene transfer into normal and atherosclerotic human blood vessels. *Circ Res* 82:1243–1252
21. Ross R (1986) The pathogenesis of atherosclerosis – an update. *N Engl J Med* 314:488–500
22. Stroes ESG, Kastelein JJ, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T (1997) Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. *J Clin Invest* 99:41–46
23. Tanner FC, Carr DP, Nabel GJ, Nabel EG (1997) Transfection of human endothelial cells. *Cardiovasc Res* 35:522–528
24. Tanner FC, Yang Z, Duckers E, Gordon D, Nabel GJ, Nabel EG (1998) Expression of cyclin-dependent kinase inhibitors in vascular disease. *Circ Res* 82: 396–403
25. Tanner FC, Meyer P, Greutert H, Champion C, Nabel EG, Luscher TF (2000) Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibiting human vascular smooth muscle cell proliferation. *Circulation* 101:1982–1989
26. Tanner FC, Largiadèr T, Greutert H, Yang Z, Luscher TF (2004) Nitric oxide synthase gene transfer inhibits biological features of bypass graft disease in the human saphenous vein. *J Thorac Cardiovasc Surg* 127:20–26
27. Tarpey MM, White CR, Suarez E, Richardson G, Radi R, Freeman BA (1999) Chemiluminescent detection of oxidants in vascular tissue. Lucigenin but not coelenterazine enhances superoxide formation. *Circ Res* 84:1203–1211
28. Tschudi MR, Barton M, Bersinger NA, Moreau P, Cosentino F, Noll G, Malinski T, Luscher TF (1996) Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. *J Clin Invest* 98:899–905
29. Varenne O, Pislaru S, Gillijns H, van Pelt N, Gerard RD, Zoldhelyi P, van de Werf F, Collen D, Hanssens SP (1998) Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. *Circulation* 98: 919–926
30. von der Thüsen JH, Fekkes ML, Passier R, von Zonneveld AJ, Mainfroid V, van Berkel TJC, Biessen EAL (2004) Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of postangioplasty restenosis. *Arterioscler Thromb Vasc Biol* 24:357–362
31. Wever RMF, Luscher TF, Cosentino F, Rabelink T (1998) Atherosclerosis and the two faces of endothelial nitric oxide synthase. *Circulation* 97:108–112
32. Yang Z, Simari RD, Tanner FC, Stephan D, Nabel GJ, Nabel EG (1996) Gene transfer approaches to the regulation of vascular cell proliferation. *Semin Intervent Cardiol* 1:181–184